BLRD Research Career Scientist Award Application

BLRD 研究职业科学家奖申请

• 批准号: 10594005
• 负责人: PRAN K DATTA
• 金额: --
• 依托单位: BIRMINGHAM VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-01 至 2027-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10594005
• 关键词: Academia; Afghanistan; Age Years; Alabama; American; Award; Basic Cancer Research; Binding Proteins; Biological Markers; Brain; Cancer Etiology; Cancer Patient; Cessation of life; Chemoresistance; Clinical; Cloning; Collaborations; Colorectal; Colorectal Cancer; Combined Modality Therapy; Communication; Death Records; Development; Diagnosis; Diagnostic; Discipline; Disseminated Malignant Neoplasm; Distant Metastasis; Drug resistance; Epithelium; Faculty; Family member; Fluorouracil; Funding; Gastroenterology; Grant; Health; Healthcare; Hematology; Hepatology; Human; Institution; International; Iraq; Journals; Knock-in Mouse; Knockout Mice; Korean War; Laboratories; Letters; Lung Neoplasms; Malignant Neoplasms; Malignant neoplasm of lung; Medical center; Mentors; Metastatic malignant neoplasm to brain; MicroRNAs; Military Personnel; Molecular; Mus; Nature; Neoplasm Metastasis; Non-Small-Cell Lung Carcinoma; Nucleic Acids; Oncogenes; Oncogenic; Oncology; Oncoproteins; Organoids; Paper; Pathogenesis; Patients; Pharmacologic Substance; Phase; Play; Population; Positioning Attribute; Postdoctoral Fellow; Protein Array; Proteins; Publications; Regulation; Research; Research Personnel; Risk; Role; Scientist; Seminal; Serum; Services; Signal Transduction; Small Interfering RNA; Smoke; Smoking; Therapeutic; Tobacco use; Training; Transforming Growth Factor beta; Transforming Growth Factor beta Receptors; Translational Research; Tumor Suppressor Genes; Tumorigenicity; Universities; Veterans; Vietnam; War; Woman; Work; active duty; anticancer research; beta catenin; career; chemotherapy; cigarette smoking; circulating microRNA; clinical predictors; combat; embryonic stem cell; high risk; in vivo Model; innovation; intestinal epithelium; military veteran; mortality; nanocarrier; nanoformulation; nanoparticle; nanotherapy; notch protein; novel; novel strategies; oxaliplatin; predictive marker; professor; programs; research and development; response; screening; serine-threonine kinase receptor-associated protein; stem-like cell; stemness; therapeutic target; translational cancer research; tumor; tumor progression; Academia; Afghanistan; Age Years; Alabama; American; Award; Basic Cancer Research; Binding Proteins; Biological Markers; Brain; Cancer Etiology; Cancer Patient; Cessation of life; Chemoresistance; Clinical; Cloning; Collaborations; Colorectal; Colorectal Cancer; Combined Modality Therapy; Communication; Death Records; Development; Diagnosis; Diagnostic; Discipline; Disseminated Malignant Neoplasm; Distant Metastasis; Drug resistance; Epithelium; Faculty; Family member; Fluorouracil; Funding; Gastroenterology; Grant; Health; Healthcare; Hematology; Hepatology; Human; Institution; International; Iraq; Journals; Knock-in Mouse; Knockout Mice; Korean War; Laboratories; Letters; Lung Neoplasms; Malignant Neoplasms; Malignant neoplasm of lung; Medical center; Mentors; Metastatic malignant neoplasm to brain; MicroRNAs; Military Personnel; Molecular; Mus; Nature; Neoplasm Metastasis; Non-Small-Cell Lung Carcinoma; Nucleic Acids; Oncogenes; Oncogenic; Oncology; Oncoproteins; Organoids; Paper; Pathogenesis; Patients; Pharmacologic Substance; Phase; Play; Population; Positioning Attribute; Postdoctoral Fellow; Protein Array; Proteins; Publications; Regulation; Research; Research Personnel; Risk; Role; Scientist; Seminal; Serum; Services; Signal Transduction; Small Interfering RNA; Smoke; Smoking; Therapeutic; Tobacco use; Training; Transforming Growth Factor beta; Transforming Growth Factor beta Receptors; Translational Research; Tumor Suppressor Genes; Tumorigenicity; Universities; Veterans; Vietnam; War; Woman; Work; active duty; anticancer research; beta catenin; career; chemotherapy; cigarette smoking; circulating microRNA; clinical predictors; combat; embryonic stem cell; high risk; in vivo Model; innovation; intestinal epithelium; military veteran; mortality; nanocarrier; nanoformulation; nanoparticle; nanotherapy; notch protein; novel; novel strategies; oxaliplatin; predictive marker; professor; programs; research and development; response; screening; serine-threonine kinase receptor-associated protein; stem-like cell; stemness; therapeutic target; translational cancer research; tumor; tumor progression

Dr. Pran K. Datta is currently a Research Microbiologist at the Birmingham VA Medical Center (BVAMC), AL, and a Professor at the VA-affiliated University of Alabama at Birmingham (UAB). He has a long-standing track record in the mechanistic studies of colorectal (CRC) and lung cancer. Since 2010, he has been contributing significantly to VA research and services through training, mentoring, and collaboration with VA investigators. His established expertise in basic and translational cancer research has also attracted investigators from diverse disciplines at the VA Medical Centers in the US, Vanderbilt University, and UAB, which has led to collaborative grants and high-impact publications. A seminal discovery from Dr. Datta's lab is the identification and cloning of a TGF-ß-receptor binding protein STRAP (Serine Threonine Kinase Receptor Associated Protein) that inhibits TGF-ß signaling and activates Wnt/ß-catenin and Notch signaling. The second seminal contribution of his study is to establish the role of STRAP in activating the stemness of cancer stem-like cells. His third seminal contribution is to identify a smoking-regulated miRNA signature that promotes NSCLC progression and chemoresistance. His high impact research resulted in more than 70 papers and reviews in reputable top-tier scientific journals (some of them with impact factor range 8.7-22.7). The fundamentals of the following projects are based on these high impact and highly cited papers. Around 20 of his papers are cited more than 100 times each. Project I: Translational research on colorectal cancer (CRC) pathogenesis and targeting by nanotherapy. During the last 40 years, the proportion of CRC has increased by about 15% in the veteran population and thus constitutes a significant risk for all veterans and their family members, including women, especially over 50 years of age. Consistent with this, there were more than 52,000 new cases of colorectal cancer cases in VA during the last 5 years. To combat this problem, the PI's lab will therapeutically target the pro-oncogenic functions of STRAP by siRNA-based nanoformulation in potential treatment of CRC patients as well as by sensitizing 5-FU and/or Oxaliplatin based chemotherapy. Project II: Circulating microRNAs as predictive biomarkers for brain metastasis in non-small cell lung cancer (NSCLC). Consistent with the fact that lung cancer remains the leading cause of cancer death in the US veteran population, there were 41,780 new lung cancer cases and 19,543 lung cancer deaths among the VA population during the last 5 years. The percentage of active-duty military personnel who smoked was highest during the Vietnam and Korean Wars (75%). Similarly, 60% of Afghanistan and Iraq War veterans used tobacco. The death records of 52,000 veterans of Vietnam War showed that these veterans died of lung cancer at a 58% higher rate than veterans who did not serve there. To this end, Dr. Datta's lab is trying to identify a miRNA signature in primary lung tumors that predicts NSCLC metastasis to the brain. Then this miRNA signature will be validated using serum to stratify NSCLC patients at high risk for developing brain metastasis and investigate their function in NSCLC progression and metastasis. In addition to conducting these highly innovative and high impact research programs, Dr. Datta has been recognized for his exceptional contributions to training, mentoring, and services at the local and national VA. As the Director of Research in the Hematology and Oncology Division and of the T32 Training Grant, Dr. Datta oversaw the research development and mentored junior faculty and clinical and postdoctoral fellows; a number of those are in academia with high positions. Taken together, the RCS Award is expected to assist him develop high-impact diagnostics and therapies for veterans and other Americans in need.

Pran K. Datta博士目前是伯明翰弗吉尼亚州医疗中心的研究微生物学家 （BVAMC），AL，以及伯明翰（UAB）的Alabama签发的大学教授。他有一个 结直肠癌（CRC）和肺癌的机械研究中的长期记录。自2010年以来，他有 通过培训，心理和与 VA调查人员。他在基本和翻译的癌症研究方面已建立的专业知识也吸引了 来自美国弗吉尼亚州医学中心的潜水学科的调查人员，范德比尔特大学和UAB， 这导致了协作赠款和高影响力出版物。 Datta博士实验室的第二次发现是TGF-ß受体结合的识别和克隆 蛋白表带（丝氨酸苏氨酸激酶受体相关蛋白）抑制TGF-ß信号传导和 激活Wnt/ß-catenin和Notch信号传导。他的研究的第二次贡献是建立 皮带在激活癌症样细胞的干性中的作用。他的第三个半归因是确定 吸烟调节的miRNA特征，可促进NSCLC的进展和化学抗性。他的高 Impact Research在著名的顶级科学期刊上产生了70多篇论文和评论（其中一些 它们具有影响因子范围8.7-22.7）。以下项目的基本面是基于这些较高的基础 影响和高度引用的论文。他的论文中有大约有20次被引用超过100次。 项目I：结直肠癌的转化研究（CRC）发病机理和靶向 纳米疗法。在过去的40年中，老兵的CRC比例增加了约15％ 人口，因此构成了所有退伍军人及其家人（包括妇女）的重大风险 特别是50岁以上。与此一致，有超过52,000个新案例 在过去的5年中，VA中的癌症病例。为了解决这个问题，PI的实验室将热为目标 基于siRNA的纳米成型在CRC患者的潜在治疗中的促进性功能 以及通过敏化5-FU和/或基于奥沙利铂的化学疗法。 项目II：将microRNA作为非小细胞中脑转移的预测生物标志物 肺癌（NSCLC）。与肺癌仍然是癌症死亡的主要原因的事实一致 美国退伍军人人口，有41,780例新的肺癌病例和19,543例肺癌死亡 在过去5年中的VA人口。吸烟的现役军事人员的百分比是 在越南和朝鲜战争期间最高（75％）。同样，有60％的阿富汗和伊拉克战争退伍军人 用烟草。 52,000名退伍军人的死亡记录表明，这些退伍军人死于肺 癌症比在那里服役的退伍军人高58％。为此，达塔博士的实验室试图 在原发性肺部肿瘤中识别miRNA特征，以预测NSCLC转移到大脑。然后 miRNA签名将使用血清验证，以对患有大脑的高风险进行分层NSCLC患者 转移并研究它们在NSCLC进展和转移中的功能。 除了执行这些高度创新和高影响研究计划外，Datta博士还 因其在当地和国家的培训，心理和服务方面的杰出贡献而获得认可 VA。作为血液学和肿瘤学研究总监以及T32培训补助金博士 达塔（Datta）负责研究开发，并介绍了初级教师，临床和博士后研究员； 其中的数量在学术界，头寸较高。综上所述，RCS奖有望协助 他为退伍军人和其他有需要的美国人开发了高影响力的诊断和疗法。